|
Dec 21
|
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
|
|
Dec 20
|
Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of Emphysema
|
|
Dec 19
|
13 Most Promising Healthcare Stocks According to Analysts
|
|
Dec 7
|
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
|
|
Dec 5
|
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
|
|
Nov 27
|
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
|
|
Sep 11
|
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
|
|
Sep 6
|
Google's investment arm leads $210M raise for biotech partnered with Takeda, Lilly
|
|
Apr 27
|
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
|
|
Apr 26
|
Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
|